Issue 7
Will biosimilars threaten Big Pharma dominance? Why is generic uptake so low?
Why not sign up for our future email newsletters? Sign up here.
Included in this issue:
LEAD STORY
Do Biosimilars Represent a Threat to Big Pharma?
As the industry looks to find more effective ways to manage the rising burden of genetic, autoimmune, rare diseases, and cancers, the next 10 years could be significant for companies with an interest in biologics drug products. The sector – estimated to have been worth $460 bn in 2022 – is expected to grow significantly due to rising demand in emerging markets across Asia and Latin America. As the industry aims to enhance value for patients and hiqealthcare providers, biosimilars have featured as cost-effective alternatives to branded medications.
Read more here.
FEATURED STORIES
Overcoming Brand Loyalty: Survey Suggests a Challenge for Generic Drugs
Read more here.
Nanoform and PlusVitech Collaborate to Repurpose Aprepitant for Lung Cancer Treatment
Read more here.
Sanofi's Global Restructure: Layoffs and R&D Reprioritization to Spearhead Immunoscience Focus
Read more here.
Terumo Medical Expands Manufacturing in Puerto Rico
Read more here.
SCHOTT Pharma Invests $371 Million in New US Facility for Prefillable Syringe Production
Read more here.
FDA Approves First BCMA-Targeted Relapsed or Refractory Multiple Myeloma Therapy
Read more here.
Study Reveals Many Fast-Tracked Cancer Drugs Fail to Show Long-Term Benefits
Read more here.
Rezdiffra Launches as First MASH Treatment with Promising Rapid Uptakes
Read more here.
Novo Refiles $16.5 Bn Catalent Acquisition to Extend FTC Review Period
Read more here.
FDA Halts Neumora's Schizophrenia Drug Trials Over Preclinical Safety Concerns
Read more here.
Novartis Prepares Pluvicto Filing for Earlier Prostate Cancer Stages Based on New Survival Data
Read more here.
Regeneron Ventures Launches $500 Million Fund to Accelerate Life Sciences Innovation
Read more here.
Amylyx Withdraws ALS Drug Relyvrio Following Trial Failure; Cuts 70% of Staff
Read more here.
AbbVie's Qulipta Shows Long-Term Promise for Migraine Prevention
Read more here.
Wegovy and Similar Weight Loss Drugs Explored as Potential Treatment for Heart Failure in Diabetic and Obese Patients
Read more here.
J&J to Acquire Shockwave Medical for $13.1 Billion, Boosting Cardiovascular MedTech Division
Read more here.
FDA Approves Zevtera for Multiple Bacterial Infections
Read more here.
Genmab Acquires ProfoundBio, Expands into ADC Cancer Treatments
Read more here.
Terumo Launches Study for Resorbable Microsphere Efficacy in Liver Cancer Treatment
Read more here.
Bloom Biorenewables and Valsynthèse Scale Up Sustainable Lignin Production for Polyurethane
Read more here.
